MedTrace Logo

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

NCT03495323 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-04-15

No results posted yet for this study

Summary

This research study is studying a combination of a targeted therapy and an immune therapy as a possible treatment.

The drugs involved in this study are:

* Prexasertib (LY2606368)
* LY3300054

Conditions

Interventions

DRUG

LY3300054

LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (

DRUG

Prexasertib

Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death

Sponsors & Collaborators

Principal Investigators

  • Geoffrey T Shapiro, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-16
Primary Completion
2021-02-01
Completion
2021-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03495323 on ClinicalTrials.gov